| Literature DB >> 32342824 |
Taru Aggarwal1, Ridhima Wadhwa2, Riya Gupta1, Keshav Raj Paudel3, Trudi Collet4, Dinesh Kumar Chellappan5, Gaurav Gupta6, Haribalan Perumalsamy7, Meenu Mehta2, Saurabh Satija2, Philip M Hansbro3, Kamal Dua2, Pawan Kumar Maurya8.
Abstract
Regardless of advances in detection and treatment, breast cancer affects about 1.5 million women all over the world. Since the last decade, genome-wide association studies (GWAS) have been extensively conducted for breast cancer to define the role of miRNA as a tool for diagnosis, prognosis and therapeutics. MicroRNAs are small, non-coding RNAs that are associated with the regulation of key cellular processes such as cell multiplication, differentiation, and death. They cause a disturbance in the cell physiology by interfering directly with the translation and stability of a targeted gene transcript. MicroRNAs (miRNAs) constitute a large family of non-coding RNAs, which regulate target gene expression and protein levels that affect several human diseases and are suggested as the novel markers or therapeutic targets, including breast cancer. MicroRNA (miRNA) alterations are not only associated with metastasis, tumor genesis but also used as biomarkers for breast cancer diagnosis or prognosis. These are explained in detail in the following review. This review will also provide an impetus to study the role of microRNAs in breast cancer. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: breast cancer; drug resistance; drug targeting; micro-RNA; oncomirs; oncosuppressormir
Year: 2020 PMID: 32342824 DOI: 10.2174/1871530320666200428113051
Source DB: PubMed Journal: Endocr Metab Immune Disord Drug Targets ISSN: 1871-5303 Impact factor: 2.895